Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era".

[1]  S. Fosså,et al.  Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). , 2013, Gynecologic oncology.

[2]  D. Matei,et al.  Updates in the management of ovarian germ cell tumors. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[3]  Y. Englert,et al.  Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Geraci,et al.  Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003 , 2012, Cancer.

[5]  J. Ng,et al.  Malignant ovarian germ-cell tumours. , 2012, Best practice & research. Clinical obstetrics & gynaecology.

[6]  H. Earl,et al.  Multidisciplinary management of malignant ovarian germ cell tumours. , 2011, Gynecologic oncology.

[7]  K. Main,et al.  Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  J. Visser,et al.  Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. , 2008, Human reproduction.

[9]  M. Fallat,et al.  Preservation of Fertility in Pediatric and Adolescent Patients With Cancer , 2008, Pediatrics.

[10]  T. Tanbo.  [Is fertility of the population changed?]. , 2008, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[11]  R. Pieters,et al.  Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. , 2007, The Journal of clinical endocrinology and metabolism.

[12]  D. Gershenson.  Management of ovarian germ cell tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Anna M. Miller,et al.  Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Rustin,et al.  Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Patrizio,et al.  American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Muller,et al.  Incidence and Survival Rates for Female Malignant Germ Cell Tumors , 2006, Obstetrics and gynecology.

[17]  J. Habbema,et al.  Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. , 2005, Fertility and sterility.

[18]  M. Seckl,et al.  Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours – a retrospective long-term follow-up study , 2003, British Journal of Cancer.

[19]  C. Mangioni,et al.  Survival and reproductive function after treatment of malignant germ cell ovarian tumors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Hacker,et al.  Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors , 2000, Cancer.

[21]  J. Pont,et al.  Fertility after chemotherapy for testicular germ cell cancer. , 1997, Fertility and sterility.

[22]  C. Bokemeyer,et al.  Evaluation of long-term toxicity after chemotherapy for testicular cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Gershenson.  Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Schilsky,et al.  Gonadal dysfunction in patients receiving chemotherapy for cancer. , 1980, Annals of internal medicine.